^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Jaypirca (pirtobrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
11/03/2023
Excerpt:
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: CLL/SLL with del(17p)/TP53 mutation...Useful in Certain Circumstances...Pirtobrutinib…
Source:
Title:
PIRTOBRUTINIB (LOXO-305), A NEXT GENERATION, HIGHLY SELECTIVE, NON-COVALENT BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: RESULTS FROM THE PHASE 1/2 BRUIN STUDY
Published date:
05/12/2021
Excerpt:
...17p deletion were present in 25% (20/81), TP53 mutation in 30% (27/91)...Median follow-up was 6 months (range 0.6-17.8+) for efficacy evaluable pts. The ORR was 63% with 69 PRs...Pirtobrutinib demonstrated promising efficacy in CLL/SLL pts following multiple prior lines of therapy including a covalent BTKi and a BCL2 inhibitor. Importantly, the activity of pirtobrutinib was not restricted to pts with BTK C481 mutations.
Trial ID:
Source:
Title:
Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the American Society of Hematology Annual Meeting
Published date:
12/07/2020
Excerpt:
Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company...today announced clinical data from the LOXO-305 global Phase 1/2 BRUIN clinical trial in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)...In the 28 patients with a 17p deletion, TP53 mutation, or both, the ORR was 79% (22/28)...
